Project UpdateJul 13, 2026, 07:06 AM
Evaxion presents new preclinical data for EVX-V1 CMV vaccine
AI Summary
Evaxion A/S announced new preclinical data for its EVX-V1 cytomegalovirus (CMV) vaccine program, presented at the International Herpesvirus Workshop 2026. The data supports the multi-component concept of EVX-V1, demonstrating the potential of AI-Immunology™ discovered novel T-cell epitopes to improve control of acute infection, latency, and reactivation in CMV-infected mice. EVX-V1 aims to be a broadly protective vaccine, combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens, addressing a significant clinical challenge with no licensed vaccine currently available.
Key Highlights
- Evaxion presented new preclinical data for its EVX-V1 cytomegalovirus (CMV) vaccine program.
- Data was presented at the International Herpesvirus Workshop 2026 in Montreal, Canada.
- New data demonstrates potential to improve control of acute infection, latency, and viral reactivation.
- EVX-V1 combines novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens.
- AI-Immunology™ discovered novel T-cell epitopes showed efficacy in CMV-infected mice.
- The CMV treatment market was valued at $474.6 million in 2023, with a projected 6.6% CAGR (2024-2032).
Price Impact
More from EVAX